论文部分内容阅读
为研究血清可溶性CD44V6(sCD44V6)在胃癌诊断、手术切除彻底性判定及预后判断方面的价值,采用sCD44V6 ELISA试剂盒对66例胃癌患者,30例胃溃疡患者和32名正常健康献血者的血清进行检测。结果显示胃癌患者血清sCD44V6浓度显著高于胃溃疡患者及正常健康献血者(均P<0.01),根治术后患者血清sCD44V6浓度较术前明显降低(P<0.01),呈浸润性生长者较呈局限性生长者高(P<0.05),且随淋巴结转移程度加重而明显上升(P<0.05),但与胃癌病期、细胞分化程度、血管癌栓与否无明显关系(均P>0.05)。提示sCD44V6检测在胃癌辅助诊断、手术彻底性和淋巴结转移程度判定、区别局限型癌和浸润型癌及胃癌预后判断方面有重要价值。
To evaluate the value of serum soluble CD44V6 (sCD44V6) in the diagnosis of gastric cancer, thorough determination of surgical resection, and prognosis assessment, sCD44V6 ELISA kit was used to measure the serum of 66 patients with gastric cancer, 30 patients with gastric ulcer, and 32 normal healthy blood donors. Testing. The results showed that the serum sCD44V6 concentration was significantly higher in patients with gastric cancer than in patients with gastric ulcer and normal healthy blood donors (all P<0.01). The serum sCD44V6 concentration after radical surgery was significantly lower than before surgery (P<0.01), compared with patients with invasive growth. Localized growth was high (P<0.05), and it increased significantly with aggravation of lymph node metastasis (P<0.05). However, it was not significantly related to the stage of gastric cancer, cell differentiation, or vascular thrombus (P>0.05). . The detection of sCD44V6 has important value in the diagnosis of gastric cancer, the thoroughness of surgery and the determination of the degree of lymph node metastasis, the differentiation of localized carcinoma, invasive carcinoma, and the prognosis of gastric cancer.